North America Cell Therapy Market By Therapy Type (Autologous and Allogeneic), By Therapeutic Area (Malignancies, Autoimmune Disorders, Musculoskeletal Disorders, Dermatology and Others), By End User (Academic & Research Institutes and Hospitals & Clinics), By Cell Type (Stem Cell, Umbilical Cord-Derived, Adipose-Derived Stem Cell, Non-Stem Cell, Bone Marrow, Blood and Others), By Country, Growth Potential, Industry Analysis Report and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the North America Cell Therapy Market
The North America Cell Therapy Market would witness market growth of 24.8% CAGR during the forecast period (2020-2026). Cell therapy technologies have a vital role to play in the domain of medicine and cell therapy is bound to become an aspect of medical practice.
Cell therapy technologies have common functionality as cancer vaccines, gene therapy, tissue engineering, drug delivery, and regenerative medicine. Procedures of delivery of cell therapy products vary from injections to surgical implantation by utilizing some specific equipment. Cell therapy finds potential applications in various kinds of disorders, and cancer & nervous systems are the major ones. Other applications involve diabetes mellitus, genetic disorders, diseases of bones and joints, cardiac disorders (myocardial infarction and heart failure), and wounds of the skin & soft tissues.
A surge in adoption of human cells for cell therapy research, technological developments in the domain of cell therapy, and rise in occurrences of diseases like cancer and cardiac abnormalities are the major aspects that boost the development of the market. Moreover, the formulation of strict government norms with respect to the utilization of cell therapy would hamper the development of the cell therapy market. However, a rise in the number of norms that aim to support stem cell therapy and a surge in investments for R&D activities in emerging countries would present new growth avenues for the market in the next few years.
Moreover, the domain of regenerative medicine is going through various developments, further anticipated to provide effective treatment solutions for chronic diseases. Various companies in the developing regions, like Canada, are working hard to explore the undiscovered potential of the market for cell therapy. For example, RepliCel is investing heavily in various projects of regenerative medicine. For example, in February 2021, the company made an announcement regarding the plans for the commercialization and clinical testing of 3 extra technologies in Japan. These involve 2 cell-based therapies – one for skin rejuvenation and the other for tendon regeneration.
The US market dominated the North America Allogeneic Market by Country 2019, and would continue to be a dominant market till 2026. The Canada market is experiencing a CAGR of 29.7% during (2020 - 2026). Additionally, The Mexico market would witness a CAGR of 28.7% during (2020 - 2026).
The Malignancies market dominated the Canada Cell Therapy Market by Therapeutic Area 2019, thereby, achieving a market value of $767.2 million by 2026. The Autoimmune Disorders market is showcasing a CAGR of 29% during (2020 - 2026). Additionally, The Musculoskeletal Disorders market is estimated to grow at a CAGR of 28.6% during (2020 - 2026).
Based on Therapy Type, the market is segmented into Autologous and Allogeneic. Based on Therapeutic Area, the market is segmented into Malignancies, Autoimmune Disorders, Musculoskeletal Disorders, Dermatology and Others. Based on End User, the market is segmented into Academic & Research Institutes and Hospitals & Clinics. Based on Cell Type, the market is segmented into Stem Cell, Umbilical Cord-Derived, Adipose-Derived Stem Cell, Non-Stem Cell, Bone Marrow, Blood and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fujifilm Holdings Corporation, Smith & Nephew PLC, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Medipost Co., Ltd., Stemedica Cell Technologies, Inc., NuVasive, Inc., Avantor, Inc., Vericel Corporation, and Pharmicell Co., Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Therapy Type
By Therapeutic Area
- Autoimmune Disorders
- Musculoskeletal Disorders
By End User
- Academic & Research Institutes
- Hospitals & Clinics
By Cell Type
- Stem Cell
- Umbilical Cord-Derived
- Adipose-Derived Stem Cell
- Non-Stem Cell
- Bone Marrow
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Fujifilm Holdings Corporation
- Smith & Nephew PLC
- Kolon TissueGene, Inc.
- JCR Pharmaceuticals Co., Ltd.
- Medipost Co., Ltd.
- Stemedica Cell Technologies, Inc.
- NuVasive, Inc.
- Avantor, Inc.
- Vericel Corporation
- Pharmicell Co., Ltd.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free